Data gathered: January 2
AI Stock Analysis - Caribou Biosciences (CRBU)
Analysis generated December 9, 2024. Powered by Chat GPT.
Caribou Biosciences is a biotechnology firm specializing in genome editing technology. Leveraging CRISPR technology, the company aims to develop transformative therapeutic solutions. Caribou focuses on cutting-edge science to create treatments for serious diseases, which places it in a high-risk, high-reward bracket of the biotech industry.
Stock Alerts - Caribou Biosciences (CRBU)
 |
Caribou Biosciences | January 2 AI Score is up by 20.1% in the last couple of days. |
|
Caribou Biosciences | January 2 Price is up by 5.7% in the last 24h. |
|
Caribou Biosciences | December 30 Price is down by -5.1% in the last 24h. |
|
Caribou Biosciences | December 26 Price is down by -5.3% in the last 24h. |
Alternative Data for Caribou Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | 45 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,406 | Sign up | Sign up | Sign up |
| Twitter Followers | 6,565 | Sign up | Sign up | Sign up |
| Twitter Mentions | 12 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 59 | Sign up | Sign up | Sign up |
| Linkedin Employees | 167 | Sign up | Sign up | Sign up |
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally.
| Price | $1.68 |
| Target Price | Sign up |
| Volume | 1,360,000 |
| Market Cap | $144M |
| Year Range | $1.56 - $3.83 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Medical Devices |
In the news
Stockholder Notice: Robbins LLP Informs Stockholders of Caribou Biosciences, Inc. of the Class Action LawsuitJanuary 2 - GlobeNewswire |
|
 |
Caribou Biosciences appoints Sri Ryali as CFOJanuary 2 - Thefly.com |
 |
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBUJanuary 1 - Investing.com |
|
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou BiosciencesJanuary 1 - Investing.com |
|
ROSEN, LEADING INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBUDecember 31 - Investing.com |
CRBU Bronstein, Gewirtz & Grossman LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitDecember 31 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 2M | 10M | -8.4M | -35M | -38M | -0.382 |
| Q2 '24 | 3.5M | 11M | -8M | -38M | -43M | -0.436 |
| Q1 '24 | 2.4M | 15M | -12M | -41M | -45M | -0.460 |
| Q4 '23 | 19M | 9.7M | 9.1M | -35M | -37M | -0.390 |
| Q3 '23 | 24M | 9.7M | 14M | -10M | -15M | -0.120 |
Insider Transactions View All
| Rizvi Syed Ali-aamir filed to sell 59,373 shares at $6.3. January 20 '23 |
| Fischesser Ryan filed to sell 110,366 shares at $10.8. October 7 '22 |
| Kanner Steven filed to sell 302,059 shares at $11.2. August 26 '22 |
| Fischesser Ryan filed to buy 102,264 shares at $2.7. January 12 '22 |
| Fischesser Ryan filed to buy 109,082 shares at $4.1. January 12 '22 |
Similar companies
Read more about Caribou Biosciences (CRBU) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Caribou Biosciences?
The Market Cap of Caribou Biosciences is $144M.
What is the current stock price of Caribou Biosciences?
Currently, the price of one share of Caribou Biosciences stock is $1.68.
How can I analyze the CRBU stock price chart for investment decisions?
The CRBU stock price chart above provides a comprehensive visual representation of Caribou Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Caribou Biosciences shares. Our platform offers an up-to-date CRBU stock price chart, along with technical data analysis and alternative data insights.
Does CRBU offer dividends to its shareholders?
As of our latest update, Caribou Biosciences (CRBU) does not offer dividends to its shareholders. Investors interested in Caribou Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Caribou Biosciences?
Some of the similar stocks of Caribou Biosciences are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
.